Evaluating the Benefits of a Third MMRV Vaccine Dose for Adults in Alberta

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates whether a third dose of the measles-mumps-rubella-varicella (MMRV) vaccine can enhance immune responses in women who have low antibody levels after receiving the standard two doses. It focuses on assessing both humoral and cell-mediated immune responses to determine the effectiveness of additional vaccination in preventing infections. The study will not administer the vaccine but will analyze serological data from participants to understand their immune status better. The findings aim to clarify the protection levels in highly vaccinated populations, particularly concerning prenatal health risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women who are pregnant and have undergone routine prenatal screening for rubella antibodies.

Exclusion Criteria:

* Women younger than 18 years of age

Where it's running

• University of Alberta
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Study coordinator: Carmen Charlton, PhD
• Email: carmen.charlton@albertahealthservices.ca
• Phone: 1 (780) 407-8975

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing vaccine responses in kidney transplant patients and their healthy cohabitants

  This study is testing how well the shingles vaccine works in kidney transplant patients on different medications compared to their healthy family members.

  Recruiting Central Adelaide Local Health Network Incorporated · Adelaide, South Australia · NCT06262776

• Examining how antibiotics affect immune responses to vaccines

  This study tests how taking antibiotics affects the immune response to vaccines in healthy adults aged 18-35.

  Recruiting Phase 4 South Australian Health and Medical Research Institute · Adelaide, South Australia · NCT06148025

• Enhancing COVID-19 vaccine response in older adults with Thymalfasin

  This study is testing if a medication called Thymalfasin can help older adults respond better to their COVID-19 booster shots.

  Recruiting Phase 1 The Methodist Hospital Research Institute · Houston, Texas · NCT06821100

• How kidney failure changes antibody responses to influenza and COVID vaccines

  This project will see if adults on chronic dialysis make as much protective antibody after influenza or SARS‑CoV‑2 vaccination as people without kidney disease.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan and 2 other locations · NCT06635525

• Understanding how long vaccines protect against infections

  This study is testing how long the protection from the yellow fever and flu vaccines lasts in people aged 18-50 to help improve future vaccines.

  Recruiting at 3 sites Phase 4 Emory University · Atlanta, Georgia and 2 other locations · NCT05801978

• FluMist versus injected flu shot: immune responses in the nose and lungs of young adults

  This trial will see if the FluMist nasal vaccine causes different immune responses in the blood, nose, and lungs than the standard injected flu shot in healthy adults aged 18 to 40.

  Recruiting Phase 4 Washington University School of Medicine · St Louis, Missouri · NCT07177417

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.